Market Research Reports

  Today, digital biomarkers are frequently used for diagnosis and follow-up within therapy. They are objective, quantitative aspects of biological processes that are linked to medical indications, symptoms, surrogate endpoints, and clinical endpoints. There are multiple undergoing studies on how heterogeneous data may be accessible to deduce equivalents to conventional biomarkers when it comes to digital health and the use of smart devices that enable pervasive sensing of surrounding factors such as vital signs. Digital biomarkers have multiple applications across the healthcare industry, and an increasing adoption rate has been observed over the past few years. During the COVID-19 pandemic, technological advancements such as the integration of software and artificial intelligence (AI) in wearable devices, rising adoption of mHealth applications, and growing interest in telemedicine and remote patient monitoring systems have all contributed to the market growth for digital biomarkers.

  Biomaterial is referred to any substance which is engineered to become biocompatible for its interaction with the biological systems. Biomaterials can be categorized as synthetic and natural. The synthetic materials consist of metals, polymers and ceramics, whereas natural biomaterials are derived from natural sources such as animal tissues or are engineered in the laboratory. Some tissues are harvested from animal sources such as cows or pigs. The interaction of these biomaterials with the human body aids in the treatment, augmentation, repairing or replacement of a tissue function of the body. The global  biomaterials market  was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031. The biomaterials market is driven by a number of factors such as superior properties of biomaterials, increasing funds/aids by the government for research purposes, increasing wound healing therapies plastic surgeries, incr

  Technological developments, such as precision medicine, next-generation sequencing (NGS), and long-read sequencing have made significant advances in science and technology and simultaneously opened avenues for public healthcare. As the next frontier of medicine, the global molecular diagnostics market showcases enormous potential to completely revolutionize patient care and overall wellness in general. The importance of diagnostic tests throughout the entire procedure (i.e., prevention, detection, diagnosis, treatment, and successful management of health conditions) of treating an individual for a particular disease is as consequential as the treatment itself. It has been subjected to extensive research for further refinement of the same. Our healthcare experts have found the  molecular diagnostics market  to be one of the stable markets, and the global market is predicted to grow from $10,914.6 million in 2020 to $24,228.0 million in 2031 and is expected to grow with a CAGR of 7.38%

  The global cell-free DNA isolation and extraction market is expected to witness high growth, attributing to the rise in prevalence of cancer, increasing key player initiatives, and rising government initiatives in cell-free DNA isolation and extraction. The continued significant investments by healthcare companies to meet industry demand and the growing adoption of cell-free DNA isolation and extraction kits, tubes, and reagents among major end users are the major factors propelling the growth of the global cell-free DNA isolation and extraction market. The use of cell-free DNA isolation and extraction kits, tubes, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives in the cell-free DNA isolation and extraction market. The constant significant investments by healthcare companies to meet industry demand and the growing adoption of cell-free DNA isolation and extraction kits, tubes, and

Carrier screening are genetic tests that are used for determining if a person is a potential carrier of genetic disorders such as cystic fibrosis (CF), Down’s syndrome, Fragile X syndrome, sickle cell anemia, and spinal muscular atrophy (SMA). Carrier screening tests are extensively used by couples considering becoming pregnant to determine the risks of passing genetic anomalies to the child. This study aims at deciphering the potential of carrier screening and its larger role in bolstering the current era of precision medicine in the field of reproductive health. Carrier screening involves testing blood, saliva, or tissue extracted from inside the cheeks. In cases of genetic disorders, a person should have two affected genes to have the disorder. A person who is a carrier has only one gene for a disorder and usually does not have symptoms or have only mild symptoms. The current market for carrier screening is majorly dominated by manufacturers and service providers such as BGI Group,

  The use of infectious disease diagnostics kits, assays, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives. The increasing investments by healthcare companies to meet industry demand and the growing adoption of infectious disease diagnostics kits, tubes, and reagents among major end users are major factors propelling the growth of the Europe infectious disease diagnostics market. The  Europe infectious disease diagnostics market  was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031. Competitive Landscape The Europe infectious disease diagnostics market comprises well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for infectious disease diagnostics fr

  The global blood and plasma components market is expected to witness minimal growth, attributing to the rising burden of primary immunodeficiency diseases such as hemophilia A, von Willebrand disease (vWD), and secondary immunodeficiency diseases. Further, the increasing burden of cancer, hematologic malignancies, and organ transplantation is also contributing to the growth of the market. An increase in research and development into the use of plasma components for the treatment of neurological disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP) is also promoting the growth of the market. Moreover, initiatives taken by the major players in the global blood and plasma components market to expand and launch more blood and plasma collection centers across the world in order to fulfill the supply of blood and plasma components are the major factors that are expected to fuel the growth of the market. The  Blood and Plasma Components Market   size in 2020 was $39.58

  The global axial spondyloarthritis market is well established. Biopharmaceutical companies are trying to match themselves with new technologies in the market to improve the overall system from drug discovery to drug commercialization. The companies operating in the global axial spondyloarthritis market are now focusing more on biologics and personalized therapy to enhance therapeutics and improve patient outcomes. Also, major players such as AbbVie Inc., Eli Lilly and Company, Novartis International AG, and Pfizer Inc. are investing heavily in clinical trials for their respective therapeutic candidates to treat axial spondyloarthritis. Increasing investments in the research and development of drug manufacturing is one of the major opportunities in the global axial spondyloarthritis market. The global  axial spondyloarthritis market  was estimated to be at $1,873.8 million in 2021, which is expected to grow with a CAGR of 13.44% and reach $7,937.8 million by 2032. The growth in the gl